Document is current
Any future updates will be listed below
-
Authors
Kumar, Princy
Clarke, Amanda E.
Jonsson-Oldenbüttel, Celia
Deltoro, Miguel García
Di Giambenedetto, Simona
Brites, Carlos
Hocqueloux, Laurent
Lu, Po-Liang
Oyee, James
Oglesby, Alan
Wynne, Brian
Jones, Bryn
Evitt, Lee A.
Fox, Dainielle
Kisare, Michelle
Priest, Julie https://orcid.org/0000-0002-7854-6260
-
Funding
Funding for this research was provided by:
ViiV Healthcare (ViiV Healthcare)
- License Information
-
More Information
Article History
Accepted: 21 August 2024
First Online: 3 September 2024
Declarations
:
: This study was designed in agreement with the International Conference on Harmonization Good Clinical Practice and adhered to the principles of the Declaration of Helsinki. Study documents were reviewed and approved by national, regional, or investigational center ethics committees or institutional review boards.
: Written informed consent was obtained before participant screening.
: Not applicable.
: PK has received grants from Gilead, Merck, Theratechnologies, and ViiV Healthcare/GSK (paid to institution); has received consulting fees from and participated in data safety monitoring/advisory boards for Gilead, Merck, and ViiV Healthcare/GSK; and holds stock/stock options in Gilead, GSK, Johnson & Johnson, Merck, Moderna, and Pfizer. AEC has received grants from Gilead, GSK, MSD, and ViiV Healthcare (paid to institution); speaker fees from MSD; travel/meeting support from Gilead and ViiV Healthcare; and has participated in advisory boards for MSD, Theratechnologies, and ViiV Healthcare. CJ-O has received consulting fees from GSK and ViiV Healthcare; honoraria from AbbVie, CCO, Gilead, GSK, Janssen-Cilag, and ViiV Healthcare; payment for expert testimony from GSK and ViiV Healthcare; travel/meeting support from CCO, Gilead, GSK, Janssen-Cilag, MSD, and ViiV Healthcare; has participated in data safety monitoring/advisory boards for Gilead, GSK, Janssen-Cilag, MSD, and ViiV Healthcare; and holds a leadership role with BAGNAE. MGD has received grants and honoraria from and participated in data safety monitoring/advisory boards for AbbVie, Gilead, Janssen, MSD, and ViiV Healthcare; has received meeting/travel support from Gilead and Janssen; and has received equipment/materials from Gilead. SDG has no competing interests. CB has received research grants from GSK and Pfizer and received speaker fees from and participated in advisory boards for Gilead, GSK, and Merck. LH has received honoraria and meeting/travel support from Gilead, MSD, and ViiV Healthcare. P-LL has no competing interests. JO, AO, BW, BJ, LAE, DF, MK, and JP are employees of GSK or ViiV Healthcare and may own stock in GSK.
